EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights

Rupali Kohal, Bhavana, Preety Kumari, Arun Kumar Sharma, Ghanshyam Das Gupta, Sant Kumar Verma

Bioorganic & Medicinal Chemistry Letters · 2024

DOI: 10.1016/j.bmcl.2024.129674 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2024. Verfasst von Rupali Kohal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, Punjab, India. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Proto-Oncogene Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Indo Soviet Friendship College of Pharmacy, Department of Science and Technology, Ministry of Science and Technology, India, Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fyn, Blk, and Lyn are part of a group of proteins called Src family kinases. They are crucial in controlling cell communication and their response to the growth, changes, and immune system. Blocking these proteins with inhibitors can be a way to treat diseases where these proteins are too active. The primary mode of action of these inhibitors is to inhibit the phosphorylation of Fyn, Blk, and Lyn receptors, which in turn affects how signals pass within the cells. This review shows the structural and functional aspects of Fyn, Blk, and Lyn kinases, highlighting the significance of their dysregulation in diseases such as cancer and autoimmune disorders. The discussion encompasses the design strategies, SAR analysis, and chemical characteristics of effective inhibitors, shedding light on their specificity and potency. Furthermore, it explores the progress of clinical trials of these inhibitors, emphasizing their potential therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-fynsrc-Family KinasesPhosphorylation

Stichwörter der Autor:innen

Autoimmune disordersBlk inhibitorsCancerFyn inhibitorsKinase signallingLyn inhibitorsProtein tyrosine kinases

Substanzen

Protein-Tyrosine KinasesProto-Oncogene Proteins c-fynProto-Oncogene Proteinssrc-Family Kinases

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, Punjab, India.
  • Department of Pharmacology, ISF College of Pharmacy, Moga 142 001, Punjab, India.
  • Department of Pharmaceutics, ISF College of Pharmacy, Moga 142 001, Punjab, India.
  • Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, Punjab, India. Electronic address: santkumarverma19@gmail.com.

Förderung

  • Indo Soviet Friendship College of Pharmacy
  • Department of Science and Technology, Ministry of Science and Technology, India
  • Science and Engineering Research Board

Zitieren

APA

Kohal, R., Bhavana, Kumari, P., Sharma, A. K., Gupta, G. D., & Verma, S. K. (2024). Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2024.129674

Vancouver

Kohal R, Bhavana, Kumari P, Sharma AK, Gupta GD, Verma SK. Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights. Bioorganic & Medicinal Chemistry Letters. 2024. doi:10.1016/j.bmcl.2024.129674

BibTeX
@article{Kohal2024,
  author = {Kohal, Rupali and Bhavana and Kumari, Preety and Sharma, Arun Kumar and Gupta, Ghanshyam Das and Verma, Sant Kumar},
  title = {Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2024},
  doi = {10.1016/j.bmcl.2024.129674}
}
Kostenlos starten →